
Health Care
Viewpoints
Filter by:
The Final 60-Day Rule Is Finally Here!
February 11, 2016 | Blog | By Karen Lovitch
The Centers for Medicare & Medicaid Services (CMS) has finally published the long-awaited final rule establishing a process for Medicare Part A and B providers and suppliers to report and return overpayments within 60 days (the “60-day rule").
Read more
Deciphering the Final AMP Rule – Key Provisions Impacting Pharmacies, PBMs, and Manufacturers
February 10, 2016 | Advisory | By Theresa Carnegie, Lauren Moldawer
In late January, the Centers for Medicare & Medicaid Services (“CMS”) released the much anticipated Covered Outpatient Drugs Final Rule with Comment (the “AMP Final Rule”).
Read more
CMS Takes Action Against Network Transparency While New Jersey Legislation Hits a Snag
February 10, 2016 | Blog
Just as the Centers for Medicare & Medicaid Services (CMS) began holding federal health care plans accountable for their provider network transparency obligations, the New Jersey legislature stalled in its bid to pass a law that would require hospitals and physicians to disclose whether they are in or out-of-network with a patient’s insurance plan before providing treatment.
Read more
Positive FDA Advisory Committee Vote for First Monoclonal Antibody Biosimilar - But Will Patent Dispute Delay Launch?
February 10, 2016 | Blog | By Joanne Hawana
Tuesday, February 9th was a busy day for Korean biologics company Celltrion Inc. The company had its proposed biosimilar CT-P13 before the FDA Arthritis Advisory Committee as well as a hearing in federal court in Massachusetts as part of the patent dispute with the manufacturer of the reference biologic, Remicade (infliximab), Janssen Biotech.
Read more
OMB Finalizes Review of 60-Day Overpayment Rule
February 9, 2016 | Blog | By Brian Dunphy
The Office of Management and Budget completed its review of the long-awaited final rule establishing a process for Medicare Part A and B providers and suppliers to report and return overpayments within 60 days (the “60-day rule”). As a result, the final 60-day rule will likely be published soon.
Read more
Behind the Curtain: Shkreli was NOT the Big Story on the Hill Today
February 4, 2016 | Blog
Congress’s complex relationship with prescription drugs was on display today in the House of Representatives. In the House Committee on Oversight and Government Reform (OGR), Martin Shkreli pleaded the 5th at a hearing investigating drug pricing.
Read more
Telemedicine Momentum Picking up Steam as New Legislation Introduced in U.S. Senate
February 3, 2016 | Blog | By Alexander Hecht
Today, a bipartisan group of Senators led by Senator Brian Schatz (D-HI) and Senator Roger Wicker (R-MS) have unveiled legislation that would expand the use of telemedicine and remote patient monitoring under Medicare.
Read more
ICYMI: Biosimilars and FDA Regulatory Webinar
February 2, 2016 | Blog | By Joe Rutkowski
Our Biosimilar webinar series continued this month with Linda Bentley and Joanne Hawana’s Biosimilars FDA/Regulatory Overview presentation.
Read more
FDA Releases Draft Guidance for Medical Device Cybersecurity
February 1, 2016 | Blog
It seems that everything in our life is getting connected to the Internet. We now live in an age where household items like refrigerators have Internet-connected LCD screens and privacy experts talk about the so-called "Internet of Things." Medical devices are increasingly becoming connected as well, and like any connected device, they are at risk of getting hacked.
Read more
The Challenge of Non-Interference
January 29, 2016 | Blog
To understand the policy challenge created by repeal of the non-interference clause, consider this simple example. Acme Drug Company brings a drug to the market as a single source innovator.
Read more
CBO’s Budget Forecast and the Silver Tsunami
January 28, 2016 | Blog
This week, the Congressional Budget Office (CBO) released a projection that shows Medicare enrollment will grow by more than 30 percent in the next decade alone, and the number of seniors will steadily grow from 55 million today to more than 80 million by 2036.
Read more
Massachusetts Health Care Reform – Full Speed Ahead; Health Policy Commission 2015 Cost Trends Report
January 27, 2016 | Blog | By Daria Niewenhous
The Massachusetts Health Policy Commission (HPC) has issued its 2015 Cost Trends Report, based on the HPC’s annual health care cost growth hearings.
Read more
Thirteen Ways to Contain Health Care Costs in Massachusetts: The Health Policy Commission Issues Its 2015 Report and Recommendations
January 27, 2016 | Alert | By Stephen Weiner
In 2012 Massachusetts adopted the most recent in a series of comprehensive legislative approaches to health care reform, Chapter 224 of the Acts of 2012 (Chapter 224), which focused especially on addressing the drivers of health care costs in the Commonwealth.
Read more
Safety of Both Devices and Drugs Need to Be Better Tracked, FDA Hears from Oversight Bodies
January 26, 2016 | Blog | By Joanne Hawana
FDA lacks the appropriate data to effectively conduct post market surveillance and safety tracking activities, according to two reports released earlier this month.
Read more
Drug Costs, Risk Adjustment Drive Q2 Health Insurance Rate Increases
January 26, 2016 | Advisory | By Julie Cox, Stephen Weiner, Sasha Dudding
The Massachusetts Division of Insurance (DOI) recently held a two-day hearing on rate changes proposed by Massachusetts health insurance plans to be effective for the second quarter of 2016 (Q2).
Read more
Members of Ophthalmologist Group Charged with Illegal Boycott of Health Plan
January 24, 2016 | Alert | By Bruce Sokler, Robert Kidwell, Farrah Short
An ophthalmologist cooperative in Puerto Rico settled charges with the Federal Trade Commission (“FTC”) last week that it orchestrated an illegal boycott of a health plan.
Read more
Senate Working Group Considers Telehealth Policy Changes to Medicare
January 21, 2016 | Blog | By Carrie Roll
In keeping with the boom of telehealth legislation introduced last year at both the state and federal level, the Senate Finance Committee is considering several policy changes that, if ultimately enacted, could make telehealth the preferred method of care delivery for millions of Medicare beneficiaries living with chronic conditions.
Read more
ML Strategies Publishes Washington Outlook for 2016
January 20, 2016 | Blog | By Bridgette Keller
Earlier today, my colleagues at ML Strategies published the Washington Outlook for 2016, offering their insights about what we might expect from Capitol Hill and the Administration in the coming year.
Read more
Employment Matters: “Wrap” Documents for Employee Health and Welfare Plans
January 15, 2016 | Blog
On Tuesday, our colleague, Patricia Moran, discussed the importance of employers using “wrap” documents for certain health and welfare plans on Mintz Levin’s Employment Matters Blog.
Read more
Health Care Enforcement Report: A Look Back at 2015 and a Forecast for 2016
January 11, 2016 | Blog | By Brian Dunphy
My colleagues Hope Foster, Larry Freedman, and Bridget Rohde, members of Mintz Levin’s Health Care Enforcement Defense group, recently published a report surveying health care enforcement trends and developments in 2015 and forecasting what these developments herald for 2016.
Read more
Explore Other Viewpoints:
- Data Centers & Digital Infrastructure
- AI: The Washington Report
- Antitrust
- Appellate
- Arbitration, Mediation & Alternate Dispute Resolution
- Artificial Intelligence
- Awards
- Bankruptcy & Restructuring
- California Land Use
- Cannabis
- Class Action
- Complex Commercial Litigation
- Construction
- Consumer Product Safety
- Corporate Governance (ESG)
- Cross-Border Asset Recovery
- DEI Legal Developments
- Debt Financing
- Direct Investing (M&A)
- Diversity
- EB-5 Financing
- Education & Nonprofits
- Employment
- EnforceMintz
- Environmental (ESG)
- Environmental Enforcement Defense
- Environmental Law
- Environmental, Social, and Corporate Governance (ESG)
- FDA Regulatory
- False Claims Act
- Federal Circuit Appeals
- Financial Institution Litigation
- Government Law
- Growth Equity
- Health Care
- Health Care Compliance, Fraud and Abuse, & Regulatory Counseling
- Health Care Enforcement & Investigations
- Health Care Transactions
- Health Information Privacy & Security
- IP Due Diligence
- IPRs & Other Post Grant Proceedings
- Immigration
- Impacts of a New US Administration
- Insolvency & Creditor Rights Litigation
- Institutional Investor Class Action Recovery
- Insurance & Financial Services
- Insurance Consulting & Risk Management
- Insurance and Reinsurance Problem-Solving & Dispute Resolution
- Intellectual Property
- Investment Funds
- Israel
- Licensing & Technology Transactions
- Life Sciences
- Litigation & Investigations
- M&A Litigation
- ML Strategies
- Medicare, Medicaid and Commercial Coverage & Reimbursement
- Mergers & Acquisitions
- Patent Litigation
- Patent Prosecution & Strategic Counseling
- Pharmacy Benefits and PBM Contracting
- Portfolio Companies
- Privacy & Cybersecurity
- Private Client
- Private Equity
- Pro Bono
- Probate & Fiduciary Litigation
- Products Liability & Complex Tort
- Projects & Infrastructure
- Public Finance
- Real Estate Litigation
- Real Estate Transactions
- Real Estate, Construction & Infrastructure
- Retail & Consumer Products
- Securities & Capital Markets
- Securities Litigation
- Social (ESG)
- Special Purpose Acquisition Company (SPACs)
- Sports & Entertainment
- State Attorneys General
- Strategic IP Monetization & Licensing
- Sustainable Energy & Infrastructure
- Tax
- Technology
- Technology, Communications & Media
- Technology, Communications & Media Litigation
- Trade Secrets
- Trademark & Copyright
- Trademark Litigation
- Unified Patent Court (UPC)
- Value-Based Care
- Venture Capital & Emerging Companies
- White Collar Defense & Government Investigations
- Women's Health and Technology